Skip to main content

CORRECTION article

Front. Oncol., 01 February 2024
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 14 - 2024 | https://doi.org/10.3389/fonc.2024.1372295

Corrigendum: Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report

This article is a correction to:

  1. Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report

    1. Read original article
Barbara Castelli,*Barbara Castelli1,2*Carla FonteCarla Fonte2Milena Guidi,Milena Guidi1,2Marco TelliniMarco Tellini2Marco Di NicolaMarco Di Nicola2Alessandro IaconoAlessandro Iacono3Anna Maria BuccolieroAnna Maria Buccoliero4Daniela GretoDaniela Greto5Lorenzo GenitoriLorenzo Genitori6Iacopo SardiIacopo Sardi2
  • 1Health Sciences Department, University of Florence, Florence, Italy
  • 2Neuro-Oncology Unit, Meyer Children’s Hospital IRCCS, Florence, Italy
  • 3Radiology Unit, Meyer Children’s Hospital IRCCS, Florence, Italy
  • 4Pathology Unit, Meyer Children’s Hospital IRCCS, Florence, Italy
  • 5Radiotherapy Unit, University of Florence, Florence, Italy
  • 6Neurosurgery Unit, Meyer Children’s Hospital IRCCS, Florence, Italy

A Corrigendum on
Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report.

By Castelli B, Fonte C, Guidi M, Tellini M, Di Nicola M, Iacono A, Buccoliero AM, Greto D, Genitori L and Sardi I (2023) Front. Oncol. 13:1244628. doi: 10.3389/fonc.2023.1244628

In the published article, there was an error in affiliations 2,3,4,6. Instead of “Meyer Children’s Hospital Scientific Institute for Research, Hospitalization and Healthcare (IRCCS),” it should be “Meyer Children’s Hospital IRCCS.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: low-grade gliomas, bevacizumab, irinotecan, pilocytic astrocytoma, case report

Citation: Castelli B, Fonte C, Guidi M, Tellini M, Di Nicola M, Iacono A, Buccoliero AM, Greto D, Genitori L and Sardi I (2024) Corrigendum: Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report. Front. Oncol. 14:1372295. doi: 10.3389/fonc.2024.1372295

Received: 17 January 2024; Accepted: 19 January 2024;
Published: 01 February 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Castelli, Fonte, Guidi, Tellini, Di Nicola, Iacono, Buccoliero, Greto, Genitori and Sardi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Barbara Castelli, barbara.castelli@meyer.it

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.